Lv7
3548 积分 2022-09-22 加入
Global, regional, and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis
10天前
已完结
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
1个月前
已完结
FDA Approval Summary: Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma
2个月前
已完结
Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels
2个月前
已完结
IIIB or Not IIIB: A Previously Unanswered Question
2个月前
已关闭
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
3个月前
已完结
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
4个月前
已关闭
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
4个月前
已完结
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
4个月前
已完结
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
4个月前
已完结
皖公网安备34019202002308
